David A Palma, Houda Bahig, Andrew Hope, Stephen Harrow, Brock J Debenham, Alexander V Louie, Thi Trinh Thuc Toni Vu, Edith Filion, Andrea Bezjak, Marie-Pierre Campeau, Adele Duimering, Meredith E Giuliani, Joanna M Laba, Pencilla Lang, Benjamin H Lok, X Melody Qu, Srinivas Raman, George B Rodrigues, Christopher D Goodman, Stewart Gaede, Julie Morisset, Andrew Warner, Inderdeep Dhaliwal, Christopher J Ryerson
IMPORTANCE: Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options. OBJECTIVE: To prospectively assess the benefits and toxic effects of SABR in this patient population. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted at 6 academic radiation oncology institutions, 5 in Canada and 1 in Scotland, with accrual between March 7, 2019, and January 12, 2022...
March 7, 2024: JAMA Oncology